RT Journal Article SR Electronic T1 Neutralization of SARS-CoV-2 Omicron pseudovirus by BNT162b2 vaccine-elicited human sera JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.12.22.21268103 DO 10.1101/2021.12.22.21268103 A1 Alexander Muik A1 Bonny Gaby Lui A1 Ann-Kathrin Wallisch A1 Maren Bacher A1 Julia Mühl A1 Jonas Reinholz A1 Orkun Ozhelvaci A1 Nina Beckmann A1 Ramón de la Caridad Güimil Garcia A1 Asaf Poran A1 Svetlana Shpyro A1 Hui Cai A1 Qi Yang A1 Kena A. Swanson A1 Özlem Türeci A1 Ugur Sahin YR 2021 UL http://medrxiv.org/content/early/2021/12/23/2021.12.22.21268103.abstract AB A new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lineage, B.1.1.529, was recently detected in Botswana and South Africa and is now circulating globally. Just two days after it was first reported to the World Health Organization (WHO), this strain was classified as a variant of concern (VOC) and named Omicron. Omicron has an unusually large number of mutations, including up to 39 amino acid modifications in the spike (S) protein, raising concerns that its recognition by neutralizing antibodies from convalescent and vaccinated individuals may be severely compromised. In this study, we tested pseudoviruses carrying the SARS-CoV-2 spike glycoproteins of either the Wuhan reference strain, the Beta, the Delta or the Omicron variants of concern with sera of 51 participants that received two doses or a third dose (≥6 months after dose 2) of the mRNA-based COVID-19 vaccine BNT162b2. Immune sera from individuals who received two doses of BNT162b2 had more than 22-fold reduced neutralizing titers against the Omicron as compared to the Wuhan pseudovirus. One month after a third dose of BNT162b2, the neutralization titer against Omicron was increased 23-fold compared to two doses and antibody titers were similar to those observed against the Wuhan pseudovirus after two doses of BNT162b2. These data suggest that a third dose of BNT162b2 may protect against Omicron-mediated COVID-19, but further analyses of longer-term antibody persistence and real-world effectiveness data are needed.Competing Interest StatementU.S. and O.T. are management board members and employees at BioNTech SE. A.M., A.W., B.G.L, J.M., J.R., M.B, N.B., O.O., S.S. and R.G. are employees at BioNTech SE. A.P. is an employee at BioNTech US. U.S., O.T. and A.M. are inventors on patents and patent applications related to RNA technology and COVID-19 vaccine. U.S., O.T., A.M., A.W., B.G.L., J.M., J.R. and R.G. have securities from BioNTech SE; H.C., Q.Y., K.A.S. are employees at Pfizer and may have securities from Pfizer.Funding StatementThis work was supported by BioNTech and Pfizer.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of the Landesaerztekammer Baden- Wuerttemberg, of the Landesamt fuer Gesundheit und Soziales Geschaeftstelle des Landes Berlin, of the Aerztekammer Schleswig Holstein, of the Medizinische Fakultaet Heidelberg and of the Universitaetsklinikum der Goethe-Universitaet Frankfurt gave ethical approval for this work. In addition, the WCG IRB gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesMaterials are available from the authors under a material transfer agreement with BioNTech.